Global Automated Compounding Devices Market- 2024-2031

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,350	196 Pages	DataM Intelligence 4Market Research LLP	February, 2025	DTAM19614117

Best Price Guarantee
Price	from $4,350
Length	196 Pages
Publisher	DataM Intelligence 4Market Research LLP
Published Date	February, 2025
SKU	DTAM19614117

Market Global Automated Compounding Devices Market is expected to reach at a high CAGR during the forecast period 2024-2031.

Automated Compounding Systems (ACS), also known as Pharmacy Automation Systems or Automated Compounding Devices (ACD), are innovative machines used in healthcare settings, primarily in pharmacies and hospitals, to manufacture specialised drugs and intravenous (IV) solutions. The manufacturing of sterile and non-sterile drugs has become more accurate, safe, and efficient thanks to these equipment, which have revolutionised the industry.

In hospitals and healthcare facilities, ACDs are often used to manufacture IV medicines and solutions. They carefully weigh out and combine the necessary medications, guaranteeing the proper dosage and lowering the chance of contamination. TPN solutions, which are individualised concoctions of nutrients and drugs for patients who are unable to receive nutrition through oral or enteral methods, are made using ACDs. The ACDs make sure that these intricate formulas are accurate and sterile.

Market Dynamics

Technological advancements in Automated Compounding Devices

For many different factors, including the goal to improve patient safety, streamline pharmacy operations, and satisfy changing healthcare needs, Automated Compounding Devices (ACDs) are always improving and developing technological improvements. For instance, in December 2022, ExactaMix Pro Automated Compounder will be made available to consumers in the United States in early 2023, according to a statement from Baxter International Inc. In comparison to ExactaMix, ExactaMix Pro offers improved security, more user-friendly and useful features, and higher processing power.

Moreover, in March 2022, according to Omnicell, Inc., the launch of IVX Station. This ground-breaking approach aims to scale the advantages of utilising IV robotic technology and make it available to the general public. New technology and improvements to current products are included in Omnicell's Winter 2022 Release, which is anticipated to benefit customers.

Additionally, by precisely preparing the necessary amount and avoiding the need to discard extra medications, ACDs can help reduce medication waste. In the medical field, shortages of ready-to-use, commercially available drugs are not unusual. In cases where commercially accessible items are not available, ACDs enable healthcare facilities to produce drugs on-site. ACDs can need a substantial initial investment, but over time, by lowering drug errors, reducing waste, and improving pharmacy operations, they can result in cost savings.

Market Dynamics: Restraint

While automated compounding devices offer several advantages for healthcare settings, there are also a number of barriers and difficulties in implementing them. For instance, ACDs may compound drug shortages in some situations because they may rely on pre-filled drug vials or cartridges; when there is a shortage of those supplies, it can affect the compounding process and healthcare professionals may be reluctant to adopt new technology or alter long-standing compounding practises.

In addition to the initial investment, ACDs require ongoing maintenance, calibration, and regular servicing, which can add to the total cost of ownership. Resistances like those mentioned above may hinder the adoption of ACDs.

Market Segment Analysis

The global automated compounding devices market is segmented based on product type, technology, component, mode of operation, end-user and region.

The Intravenous (IV) compounding systems segment from the product type segment accounted for approximately 39.7% of automated compounding devices share

Intravenous (IV) compounding systems are essential to healthcare for a number of reasons, including the critical role they provide in maintaining patient safety, enhancing drug delivery, and strengthening the overall standard of care. In healthcare, patient safety is of highest priority. By streamlining the compounding procedure, these devices cut down on the time and labour needed to create IV drugs. The companies' strategies aid in accelerating the segment's growth.

For instance, on October 08, 2021, in order to increase production, Satasairaala Hospital Pharmacy acquired the IV ICON Twins compounding system from NewIcon. The hospital pharmacy now uses a semi-automatic procedure to make antibiotics: a pump administers the solvent, but the remaining compounding steps are done by hand. Each year, this semi-automated process administers around 65,000 doses of medication. Thus, those mentioned factors boost segment expansion.

Market Geographical Share

The widespread acceptance and use of ACDIs in the North American region

The North America will continue its dominance due to the presence of the major pharmaceutical industries across the region. Moreover, the safety of patients receives top priority in the healthcare system in the United States. In keeping with the healthcare sector's dedication to maintaining patient well-being, ACDs are considered as a crucial instrument in lowering the risk of medication errors, contamination, and adverse events related to the preparation of IV medications.

The United States has a history of embracing medical technology early on. The widespread acceptance and use of ACDs in healthcare settings can be attributed to this culture of welcoming novel ideas. The United States is renowned for its contributions to healthcare technology. Continuous research and development have improved automated compounding machines, making them more dependable, user-friendly, and adaptable to varied healthcare settings. Thus, above factors boost the region growth.

COVID-19 Impact Analysis

Positive effects of the COVID-19 epidemic have been noticed in consumer demand for Automated Compounding Devices (ACDs). Sterile compounding was more important than ever because of the rise in COVID-19 cases, especially for drugs and IV solutions used in critical care. ACDs, which are renowned for their capacity to guarantee sterility and precision, were essential in satisfying this requirement.

Due to mistakes in the compounding of medications could have catastrophic repercussions, the pandemic highlighted the significance of pharmaceutical safety and precision. ACDs become even more useful in lowering medication errors thanks to their accurate measurements and safety features. To boost their capacity and capabilities during the epidemic, some healthcare systems and facilities received more funds and resources. This prompted investments in ACDs to increase the capacity and efficiency of pharmacies.

Market Major Players

The major global players in the market include Grifols, S.A, Baxter International Inc, COMECER S.p.A., ARxIUM, ICU Medical, Inc, Omnicell, Inc, EQUASHIELD, B. Braun Medical Inc., BECTON, DICKINSON AND COMPANY, SMARTCOMPOUNDERS B.V. and among others.

Key Developments
• In December 2022, the APEX Compounding System and its exclusive TPN Manager Clinical Decision Support Order Entry Software will be presented at the ASHP, according to B. Braun Medical Inc. (B. Braun). The APEX Compounding System was created expressly to fulfil the urgent needs of chemists and patients with critical conditions of all ages, from newborns to adults.

Why Purchase the Report?
• To visualize the global automated compounding devices market segmentation based on product type, technology, component, mode of operation, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of automated compounding devices market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global automated compounding devices market report would provide approximately 77 tables, 79 figures and 189 Pages.

Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

1. Methodology and Scope: 1.1. Research Methodology; 1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary: 3.1. Snippet by Product Type; 3.2. Snippet by Technology; 3.3. Snippet by Component; 3.4. Snippet by Mode of Operation; 3.5. Snippet by End-User; 3.6. Snippet by Region
4. Dynamics: 4.1. Impacting Factors; 4.1.1. Drivers; 4.1.1.1. Technological advancements in Automated Compounding Devices; 4.1.1.2. The prevalence of Cancer; 4.2. Restraints; 4.2.1. The high cost of ACD Systems; 4.2.2. Opportunity; 4.2.3. Impact Analysis
5. Industry Analysis: 5.1. Porter's Five Force Analysis; 5.2. Supply Chain Analysis; 5.3. Pricing Analysis; 5.4. Regulatory Analysis; 5.5. DMI Opinion
6. COVID-19 Analysis: 6.1. Analysis of COVID-19; 6.1.1. Scenario Before COVID; 6.1.2. Scenario During COVID; 6.1.3. Scenario Post COVID; 6.2. Pricing Dynamics Amid COVID-19; 6.3. Demand-Supply Spectrum; 6.4. Government Initiatives Related to the Market During Pandemic; 6.5. Manufacturers Strategic Initiatives; 6.6. Conclusion
7. By Product Type: 7.1. Introduction; 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type; 7.1.2. Market Attractiveness Index, By Product Type; 7.2. Intravenous (IV) Compounding Systems *; 7.2.1. Introduction; 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 7.3. Oral Liquid Compounding Systems; 7.4. TPN (Total Parenteral Nutrition) Compounding Systems; 7.5. Chemotherapy Compounding Systems
8. By Technology: 8.1. Introduction; 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology; 8.1.2. Market Attractiveness Index, By Technology; 8.2. Gravimetric Automated Compounding Devices *; 8.2.1. Introduction; 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 8.3. Volumetric Automated Compounding Devices; 8.4. Syringe-based Automated Compounding Devices
9. By Component: 9.1. Introduction; 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component; 9.1.2. Market Attractiveness Index, By Component; 9.2. Hardware *; 9.2.1. Introduction; 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 9.3. Software; 9.4. Services
10. By Mode of Operation: 10.1. Introduction; 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Operation; 10.1.2. Market Attractiveness Index, By Mode of Operation; 10.2. Fully Automated Compounding Devices*; 10.2.1. Introduction; 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 10.3. Semi-Automated Compounding Devices
11. By End-User: 11.1. Introduction; 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User; 11.1.2. Market Attractiveness Index, By End-User; 11.2. Hospitals*; 11.2.1. Introduction; 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 11.3. Ambulatory Surgical Centers; 11.4. Others
12. By Region: 12.1. Introduction; 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region; 12.1.2. Market Attractiveness Index, By Region; 12.2. North America; 12.2.1. Introduction; 12.2.2. Key Region-Specific Dynamics; 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type; 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology; 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component; 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Operation; 12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User; 12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 12.2.8.1. U.S.; 12.2.8.2. Canada; 12.2.8.3. Mexico; 12.3. Europe; 12.3.1. Introduction; 12.3.2. Key Region-Specific Dynamics; 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type; 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology; 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component; 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Operation; 12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User; 12.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 12.3.8.1. Germany; 12.3.8.2. UK; 12.3.8.3. France; 12.3.8.4. Italy; 12.3.8.5. Spain; 12.3.8.6. Rest of Europe; 12.4. South America; 12.4.1. Introduction; 12.4.2. Key Region-Specific Dynamics; 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type; 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology; 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component; 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Operation; 12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User; 12.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 12.4.8.1. Brazil; 12.4.8.2. Argentina; 12.4.8.3. Rest of South America; 12.5. Asia-Pacific; 12.5.1. Introduction; 12.5.2. Key Region-Specific Dynamics; 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type; 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology; 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component; 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Operation; 12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User; 12.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 12.5.8.1. China; 12.5.8.2. India; 12.5.8.3. Japan; 12.5.8.4. Australia; 12.5.8.5. Rest of Asia-Pacific; 12.6. Middle East and Africa; 12.6.1. Introduction; 12.6.2. Key Region-Specific Dynamics; 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type; 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology; 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component; 12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Operation; 12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
13. Competitive Landscape: 13.1. Competitive Scenario; 13.2. Market Positioning/Share Analysis; 13.3. Mergers and Acquisitions Analysis
14. Company Profiles: 14.1. Grifols, S.A *; 14.1.1. Company Overview; 14.1.2. Product Portfolio and Description; 14.1.3. Financial Overview; 14.1.4. Key Developments; 14.2. Baxter International Inc; 14.3. COMECER S.p.A.; 14.4. ARxIUM; 14.5. ICU Medical, Inc; 14.6. Omnicell, Inc; 14.7. EQUASHIELD; 14.8. B. Braun Medical Inc; 14.9. BECTON, DICKINSON AND COMPANY; 14.10. SMARTCOMPOUNDERS B.V. (*LIST NOT EXHAUSTIVE)
15. Appendix: 15.1. About Us and Services; 15.2. Contact Us